A number of other research analysts have also issued reports on the company. Zacks Investment Research raised INmune Bio from a “strong sell” rating to a “hold” rating in a report on Thursday, March 10th. Maxim Group assumed coverage on INmune Bio in a report on Friday, May 6th. They issued a “buy” rating and a $22.00 target price on the stock.
NASDAQ:INMB opened at $6.68 on Wednesday. The firm has a market cap of $119.88 million, a P/E ratio of -3.46 and a beta of 2.44. The company has a current ratio of 18.95, a quick ratio of 18.95 and a debt-to-equity ratio of 0.18. The stock’s 50 day simple moving average is $7.74 and its 200-day simple moving average is $10.08. INmune Bio has a 12-month low of $6.18 and a 12-month high of $30.37.
A number of hedge funds have recently made changes to their positions in INMB. Morgan Stanley grew its holdings in INmune Bio by 97.4% during the first quarter. Morgan Stanley now owns 3,093 shares of the company’s stock worth $37,000 after acquiring an additional 1,526 shares during the period. DG Capital Management LLC acquired a new position in INmune Bio during the third quarter worth $388,000. Geode Capital Management LLC grew its holdings in INmune Bio by 21.4% during the third quarter. Geode Capital Management LLC now owns 89,607 shares of the company’s stock worth $1,740,000 after acquiring an additional 15,813 shares during the period. Royal Bank of Canada grew its holdings in INmune Bio by 90.2% during the third quarter. Royal Bank of Canada now owns 126,411 shares of the company’s stock worth $2,455,000 after acquiring an additional 59,953 shares during the period. Finally, Marshall Wace LLP acquired a new position in INmune Bio during the third quarter worth $1,256,000. 13.91% of the stock is currently owned by hedge funds and other institutional investors.
INmune Bio Company Profile (Get Rating)
INmune Bio, Inc, a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease.
- Get a free copy of the StockNews.com research report on INmune Bio (INMB)
- Wolverine Worldwide Is Ready To Rebound
- Anheuser-Busch InBev May Need One More Quarter to Confirm a Buy Signal
- Wendy’s Growth Story Has Come To An End
- Beyond Meat Could Sizzle After Q1 Results Are Released
- Can Six Flags(SIX) or Cedar Fair (FUN) Give Investors a Thrill Later This Year?
Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.